Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715562 | 0.88 | GAA (0.41) | GAATSHRALDH1A1POLBHTT | |
| SCHEMBL15121724 | 0.87 | ALDH1A1 (0.40) | GAATSHRALDH1A1POLBHTT | |
| SCHEMBL406005 | 0.87 | GAA (0.39) | GAAALDH1A1HTTL3MBTL1MAPT | |
| SCHEMBL2824395 | 0.86 | NPC1 (0.30) | — | |
| SCHEMBL2826934 | 0.85 | NR1H2 (0.40) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL9721933 | 0.83 | TSHR (0.48) | GAATSHRALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL938094 | 0.81 | GAA (0.42) | GAATSHRALDH1A1POLBHTT | |
| SCHEMBL4374906 | 0.81 | ALDH1A1 (0.45) | GAATSHRALDH1A1POLBHTT | |
| SCHEMBL160444 | 0.79 | GAA (0.41) | GAATSHRALDH1A1POLBHTT | |
| SCHEMBL13711179 | 0.79 | GAA (0.41) | GAATSHRALDH1A1POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853586-B1 | ANTIBACTERIAL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| US-20120022107-A1 | 2-(PIPERIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022107-A1 | 2-(PIPERIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022107-A1 | 2-(PIPERIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-01-26 | — | — | US | disclosed |
| EP-2379545-A1 | 2- (PIPERIDIN-1-YL) -4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010067125-A1 | 2- (PIPERIDIN-1-YL) -4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
| US-5137896-A | Useful in treatment of gastrointestinal and psychic disorder; analgesic, antiemetic and antiulcer agent | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-11 | — | — | US | disclosed |
| US-5057525-A | Stimulators of gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-10-15 | — | — | US | disclosed |
| US-4962115-A | Stimulate motility of gastrointestinal system | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-10-09 | — | — | US | disclosed |
| EP-0076530-B1 | NOVEL N-(3-HYDROXY-4-PIPERIDINYL)BENZAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-12-11 | — | — | EP | disclosed |
| EP-0076530-A2 | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022107-A1 | 2-(PIPERIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | PIR, TLR5, ALPI | GAA 603/4885TSHR 3417/4885ALDH1A1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.